ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2010
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.
Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 105 citations in OpenAlex.
- Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- Trial
- Trial
- REAL-WORLD OUTCOMES OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE TREATED WITH RUXOLITINIB.Blood cell therapy · 2025Article
- T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation.Nagoya journal of medical science · 2023Article
- Promiscuity of Peptides Presented in HLA-DP Molecules from Different Immunogenicity Groups Is Associated With T-Cell Cross-Reactivity.Frontiers in immunology · 2022Article
- Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML relapse.Frontiers in immunology · 2022Observational
- Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI.Blood advances · 2021Article
- Multivariate Analysis of Immune Reconstitution and Relapse Risk Scoring in Children Receiving Allogeneic Stem Cell Transplantation for Acute Leukemias.Transplantation direct · 2021Article
- T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect.Nature communications · 2020Article
- HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.Frontiers in immunology · 2020Article
- Vitamin C stabilizes CD8+ iTregs and enhances their therapeutic potential in controlling murine GVHD and leukemia relapse.Blood advances · 2019Article
- Article
- Prevention and treatment of relapse after stem cell transplantation by cellular therapies.Bone marrow transplantation · 2019Review
- Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant.Blood advances · 2018Article
- Article
- Third International workshop on the biology, prevention, and treatment of relapse after stem cell transplantation.Bone marrow transplantation · 2018Article
- Graft versus tumor effects and why people relapse.Hematology. American Society of Hematology. Education Program · 2017Review
- Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?Bone marrow transplantation · 2017Article
- Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.The Journal of clinical investigation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 4 countries.
Funding
Abstract
The success of allogeneic hematopoietic stem cell transplantation (HSCT) depends on the infusion of benign stem cells as well as lymphocytes capable of participating in a graft-versus-tumor/leukemia (GVL) reaction. Clinical proof of concept is derived from studies showing increased relapse after the infusion of lymphocyte depleted hematopoietic grafts as well as the therapeutic efficacy of donor lymphocyte infusions without chemotherapy to treat relapse in some diseases. Despite this knowledge, relapse after allogeneic HSCT is common with rates approaching 40% in those with high-risk disease. In this review, we cover the basic biology and potential application to exploit adaptive T cell responses, minor histocompatibility antigens, contraction and suppression mechanisms that hinder immune responses, adaptive B cell responses and innate NK cell responses, all orchestrated in a GVL reaction. Optimal strategies to precisely balance immune responses to favor GVL without harmful graft-versus-host disease (GVHD) are needed to protect against relapse, treat persistent disease and improve disease-free survival after HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.